Blocking and reversing hepatic fibrosis in patients with chronic hepatitis B treated by traditional Chinese medicine (tablets of biejia ruangan or RGT): study protocol for a randomized controlled trial

Abstract

BackgroundChronic hepatitis B (CHB) can progress to cirrhosis, hepatocellular carcinoma (HCC) and ultimately liver-related death. Although oral antiviral therapy for patients with CHB reduces the risk of such complications, once cirrhosis is established, the benefits of antiviral therapy are not robustly demonstrated. According to traditional Chinese medicine (TCM), some Chinese herbal medicines promote blood circulation and soften hard masses, and therefore they may block and reverse hepatic fibrosis. The aim of this study is to evaluate the effects of TCM tablets of the compound biejia ruangan (RGT) administered for fibrosis, and entecavir (ETV), on the development of HCC in patients with CHB or hepatitis B virus (HBV)-related compensated cirrhosis.Methods/designThis multicenter, centrally randomized, double-blind, placebo-controlled, parallel-group study is planned to complete within 5 years. For the study, 1,000 with CHB or HBV-related compensated cirrhosis are randomly assigned in a 1:1 ratio to a treatment group (0.5 mg ETV once daily; 2 g RGT three times daily) or a control group (0.5 mg ETV once daily; 2 g RGT dummy agent three times daily). The primary end points are the development of HCC and liver-related death. Secondary end points include disease progression and overall survival.DiscussionAlthough antiviral therapy can achieve sustained suppression of HBV replication, thereby preventing cirrhosis, patients with CHB treated with nucleos(t)ide analogs (NUCs) retain a higher risk for HCC compared with patients with inactive disease. Although previous clinical trials with RGT have confirmed the efficacy of blocking and reversing hepatic fibrosis in patients with CHB or compensated cirrhosis, the long-term risk for HCC or disease progression in these patients treated with combination of RGT and NUCs compared with NUCs alone is unclear. Therefore, it is necessary to investigate the effects of the RGT blockade and reversal of hepatic fibrosis on the development of HCC in patients with CHB or HBV-related compensated cirrhosis in large, prospective, multicenter, double-blind, randomized, controlled trials in China.Trial registrationClinicalTrials.gov Identifier: NCT01965418. Date registered: 17 October 2013

Associations between prescribed Chinese herbal medicine and risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide population-based cohort study

“…A number of clinical trials have been performed to assess the therapeutic efficacy and safety of CHM products. 1 13 14 On the other hand, a recent cohort study reported that adjunctive therapy with CHM may improve the survival of patients with liver cancer. 15 Although nucleoside analogue therapy is associated with reduced risk of HCC in patients with CHB virus infection and experience fewer side effects, in many cases the drug resistance and viral variation limit their efficacy as therapeutic agents for CHB.…”

On-treatment monitoring of liver fibrosis with serum hepatitis B core-related antigen in chronic hepatitis B

“…This was a multicenter prospective sub-study of our ongoing clinical trial of regression of HBV-related liver fibrosis in China (NCT01965418)[25]. The study meets the requirements of the Declaration of Helsinki, the protocol was approved by the ethics committee of each participating institution, and written informed consent was obtained from all patients.…”

Dynamic Changes in MMP1 and TIMP1 in the Antifibrotic Process of Dahuang Zhechong Pill in Rats with Liver Fibrosis

“…Traditional Chinese medicine has been selected as an alternative treatment for liver fibrosis because of the low efficiency and unexpected side effects of the currently used therapeutic strategy [5]. Numerous herbal medicines are used for liver fibrosis therapy in clinical practice [6][7][8]. The Fuzheng Huayu formula is one of the most well-studied antifibrotic agents and has a good therapeutic effect on hepatitis B-induced cirrhosis [9,10].…”